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Background: Successful treatment of cancer with dendritic cell tumor vaccine is highly 
dependent on how effectively the vaccine migrates into lymph nodes and activates T cells. In this 
study, a simple method was developed to trace migration of dendritic cells to lymph nodes.
Methods: Superparamagnetic iron oxide (SPIO) of γ-Fe2O3 nanoparticles were prepared to 
label dendritic cells generated from bone marrow of enhanced green fluorescent protein (EGFP) 
transgenic mice, to explore the fluorescence intensity of EGFP influenced by the SPIO, and to 
make images of labeled dendritic cells with the help of magnetic resonance imaging in vitro. 
The SPIO-EGFP-labeled dendritic cells were injected into the footpads of five mice. After 
48 hours, magnetic resonance imaging, optical imaging, confocal imaging, and Prussian blue 
staining were used to confirm migration of the SPIO-EGFP-labeled dendritic cells into draining 
lymph nodes.
Results: The synthetic SPIO nanoparticles had a spherical shape and desirable superparamag-
netism, and confocal imaging and Prussian blue staining showed perfect labeling efficiency as 
well. Furthermore, the dendritic cells dual-labeled by SPIO and EGFP could migrate into lymph 
nodes after footpad injection, and could be detected by both magnetic resonance imaging and 
optical imaging simultaneously, which was further confirmed by immunohistochemistry and 
Prussian blue staining. The percentage of dendritic cells migrated to the draining lymph nodes 
was about 4%.
Conclusion: Synthetic SPIO nanoparticles are strong contrast agents with good biocompatibility, 
and EGFP transgenic dendritic cells can be labeled efficiently by SPIO, which are suitable for 
further study of the migratory behavior and biodistribution of dendritic cells in vivo.
Keywords: magnetic resonance imaging, optical imaging, dendritic cell, superparamagnetic 
iron oxide, cell tracking
Introduction
Superparamagnetic iron oxide (SPIO) nanoparticles are regarded as useful tools in 
numerous medical applications.1–3 Due to their small size, superparamagnetism, and 
inherent biocompatibility, they have been widely used in medical diagnosis, treatment, 
and even cell labeling and sorting.4–6 However, although they are promising materials 
for in vivo application, concern has been raised about their biological safety.
Dendritic cells are potent antigen-presenting cells that prominently express 
costimulatory molecules and are uniquely capable of inducing primary immune 
responses.7,8 Accumulating data on dendritic cells have shown them to induce 
strong antitumor immune responses in vitro and in vivo, and their efficacy has 
also been investigated.9–11 Essentially, dendritic cell immunotherapy is based on 
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migration of these cells from the periphery to T cells via 
afferent lymphatics to generate potent immune responses.12 
The dendritic cell migration process is complicated, 
involving a number of molecules, including chemokines, 
chemotactic receptors, adhesion molecules, and matrix 
metalloproteinases.13 Studies on dendritic cell trafficking 
have shown different migration patterns when using 
different routes of administration. Dendritic cell homing to 
the spleen and draining lymph nodes has been investigated 
after intravenous, intraperitoneal, subcutaneous, intradermal, 
and intranodal transfusion.10,14–18 Antigen-specific immune 
responses induced by dendritic cells via intranodal injection 
were similar to those after intradermal injection,10,14–16 and 
those induced by dendritic cells after intravenous infusion 
were similar to those after intradermal injection.10,18 It was 
noted that the ability of dendritic cells to migrate to lymph 
nodes was very limited after intravenous infusion, and that 
the footpad contains less fat tissue and a high density of 
lymph vessels.10,17 Thus, footpad injection was selected for 
investigation, which gave rise to similar migration efficiency 
as intradermal injection.18
Evaluation of dendritic cell migration efficiency requires 
a noninvasive imaging approach. At present, several 
noninvasive imaging methods for tracking dendritic cells 
have been reported, including planar gamma scintigraphy 
using gamma radiation-emitting radionuclides (such 
as 111inoxinate labeling),16 positron emission tomography 
with fluorine-18 labeling,19 magnetic resonance imaging 
with iron oxide magnetic nanoparticle labeling,20–22 and 
optical imaging by luciferase or fluorescent dye labeling.23,24 
Studies have indicated that noninvasive, live, and high-
resolution 7 T or 11.7 T micro-magnetic resonance imaging 
enables detailed monitoring of magnetically labeled cells 
following infusion and provided a feasible method to 
evaluate the biological behavior of infused cell-based 
therapy.25,26 Optical imaging, which can be performed at 
high spatial and temporal resolution, has a high sensitivity 
for contrast agents, and is comparable with techniques used 
in nuclear medicine.
To overcome the limitations of the low sensitivity of 
magnetic resonance imaging compared with nuclear methods 
and the limited background anatomical information obtained 
from optical imaging, the two techniques were used jointly 
to observe dendritic cell migration into lymph nodes after 
footpad administration, which were labeled efficiently by 
transgenic enhanced green fluorescent protein (EGFP) 
and SPIO.
Material and methods
Experimental agents
Ferric chloride (FeCl3 · 6H 2O), ferrous sulfate (FeSO4 · 7H2O), 
and hydrochloric acid were purchased from Sinopharm Chemical 
Reagent Co Ltd (Shanghai, China). Tetramethylammonium 
hydroxide was obtained from Shanghai Lingfeng Chemical 
Reagent Co Ltd (Shanghai, China). RPMI medium 1640, 
penicillin and streptomycin were from Gibco Invitrogen 
(Grand Island, NY). Fetal bovine serum (Gibco, Life 
Technologies, Breda, the Netherlands), recombinant 
murine granulocyte-macrophage colony-stimulating factor, 
recombinant murine interleukin-4, tumor necrosis factor-α 
(TNF-α), interleukin-1β, interleukin-6 (Peprotech, Rocky 
Hills, NJ), prostaglandin E2 (Sigma-Aldrich, St Louis, MO) 
were also used, as well as a Prussian blue staining kit (Yuanye, 
Shanghai, China) and isoflurane (Abbott, Shanghai, China). 
Triton-X (Beyotime, China), and normal goat serum, rabbit 
anti-GFP probes, and goat antirabbit Alexa 488 nm were 
also used.
Preparation of SPIO
γ-Fe2O3 nanoparticles were prepared according to our previous 
work.14 Briefly, 200 mL aqueous tetramethylammonium 
hydroxide solution 1.5 M was added to 500 mL of aqueous 
solution containing FeCl3 0.1 M and FeSO4 0.05 M, with 
vigorous stirring at room temperature for 30 minutes. The Fe3O4 
nanoparticles obtained were washed by magnetic separation 
and redispersed in water at pH 3.0 and a concentration of 
3.0 mg/mL, then oxidized into brown γ-Fe2O3 nanoparticles 
by aeration at 95°C. The γ-Fe2O3 nanoparticles obtained were 
dialyzed using an aqueous solution of hydrochloric acid at 
pH 3.0, with the final concentration adjusted to 25 mg/mL 
for cell label experiments.
The particle size and morphology of the γ-Fe2O3 nano-
particles were characterized using a transmission   electronic 
microscope (JEM-2100; JEOL, Tokyo, Japan). The 
  magnetic properties were measured using a vibrating sample 
  magnetometer (Model 7407; Lake Shore, Westerville, OH). 
Photon correlation spectroscopy was used to determine the 
hydrodynamic size distribution using a Beckman Coulter 
N4 Plus submicron particle analyzer, and surface charge 
  measurements were performed using a Beckman Coulter 
Delsa 440SX zeta potential analyzer (Indianapolis, IN).
Mice
Female C57BL/6 mice were purchased from the Animal 
Research Center of Yangzhou University, and EGFP-  transgenic 
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C57BL/6 mice were purchased from the Model Animal 
Research Center of Nanjing University, and housed in specified 
pathogen-free conditions at the Central Animal Facility,   Nanjing 
University. In a typical experiment, bone marrow was isolated 
from the femur of 8–10-week-old mice weighing 20–22 g. 
All animal experiments were performed in accordance with 
protocols approved by the Animal Care and Use Committee 
of the Medical School, Nanjing University, China.
Cell culture and labeling
Dendritic cells were generated according to our previous 
work.15 Briefly, monocytes were isolated from the bone 
marrow of the mice. The marrow monocytes were flushed 
out from the femurs and tibias, cultured with RPMI 1640 
supplemented with 10% fetal bovine serum, 50 mM 
2-mercaptoethanol, 100 mM sodium pyruvate, 100 U/mL 
penicillin, 100 mg/mL streptomycin, 10 ng/mL recombinant 
granulocyte-macrophage colony-stimulating factor, and 
1 ng/mL murine recombinant interleukin-4. On days 2 and 4, 
50% of the medium was removed and fresh medium was 
added. The released immature, nonadherent dendritic cells 
were collected on day 6. The cells were stimulated with 
TNF-α 10 ng/mL, interleukin-1β 10 ng/mL, interleukin-6 
10 ng/mL, and prostaglandin E2 1 µg/mL for 48 hours.16,17 
Mature dendritic cells were collected on day 8 and incubated 
with the SPIO 25 µg/mL for 12 hours at 37°C in 5% CO2. 
  Cellular phenotypes, viability, and function had been 
explored in our previously published work.16
Prussian blue staining
Mature EGFP transgenic dendritic cells were incubated 
with SPIO 25 µg/mL for 12 hours at 37°C in 5% CO2. Cells 
were washed three times in phosphate-buffered solution and 
cytospins were prepared. Iron labeling efficiency was verified 
by Prussian blue staining and screened at high magnification 
(400×) using a light microscope (CKX41-A32PH; Olympus, 
Tokyo, Japan). Furthermore, laser confocal fluorescence 
microscope (Fluoview, Fv10i; Olympus) was performed to 
collect the EGFP fluorescence images.
EGFP fluorescence intensity  
after SPIO labeling
Mature EGFP transgenic dendritic cells were incubated with 
SPIO 25 µg/mL for 12 hours at 37°C in 5% CO2. The cells 
were washed three times in phosphate-buffered solution. 
EGFP fluorescence intensity was studied by flow cytometry 
using Cell Quest software.
Magnetic resonance imaging  
of SPIO-labeled dendritic cells in vitro
T2*-weighted images of the SPIO were acquired with a 
Bruker Biospin 7.0 T scanner (Bruker BioSpin, Ettlingen, 
Germany) using a 38 mm rat head circular volume coil. 
For in vitro studies, 0.2 mL tubes with 1% agarose 50 µL, 
1 × 104, 1 × 105, and 1 × 106 SPIO-EGFP-labeled dendritic 
cells were placed into the tubes separately. These containers 
were positioned in the coil. The magnetic resonance sequence 
for evaluation of the cells was a fast low-angle shot gradient 
echo sequence. The parameters were set as follows: repetition 
time 471.1 msec; echo time 6.2 msec; flip angle 13 degrees; 
field of view 3.0 × 3.0 cm2; matrix (MTX), 384 × 384 mm2; 
slice thickness 0.28 mm; and interslice distance 0.53 mm.
Magnetic resonance imaging in vivo
For the in vivo studies, TNF-α (30 ng/leg)20 was preinjected 
into the footpads of both hind legs (n = 5). After 24 hours, 
C57BL/6 mice were injected in the right footpads with 
2 × 106 SPIO-EGFP-labeled dendritic cells in 40 µL of 
phosphate-buffered solution, and in the left footpad with 
only 40 µL phosphate-buffered solution as the control. After 
48 hours, the mice were anesthetized by 4% isoflurane/O2 
(v/v) inhalation, placed on a warming pad, and maintained 
on 1%–2% isoflurane/O2 (v/v) throughout the experiments. 
Magnetic resonance imaging was performed and the   phantom 
of mice popliteal lymph nodes was analyzed under the 
conditions of MSME-PD-T2, echo time 65 msec,   repetition 
time 3719.3 msec, field of view 2.70 × 2.50 cm2, MTX 
256 × 256 mm2, interslice distance 0.7 mm, slice thickness 
0.5 mm, and averages of 4.
Optical imaging ex vivo
After magnetic resonance imaging, the optical   imaging was 
performed. The bilateral popliteal lymph nodes were dissected, 
arranged on a black plate, and the optical images were obtained 
using a CRI optical imaging system   (Maestro™, 2 Maestro™ 
Ex-RRO; Hopkinton, MA). The parameter was an   excitation 
light source (484 nm, diode laser) with a cold charge-
coupled device camera (Nuance TX, Cambridge Research 
and Instrumentation, Woburn, MA) and an emission filter of 
507 nm. Ex vivo imaging data were analyzed using the Living 
Image software (v 2.50; Caliper Corporation, Newton, MA).
Immunohistochemistry
To analyze the in situ distribution of SPIO-EGFP-labeled 
dendritic cells, draining lymph nodes were dissected 
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48 hours following administration of dendritic cells. They 
were embedded in optical cutting temperature (Sakura 
Finetek USA Inc, Torrance, CA). Cryosections 5 µm thick 
were   prepared, and fixed with 4% paraformaldehyde for 
30 minutes. The sections were blocked in 0.1% Triton-X 
and 10% normal goat serum for 1 hour, and incubated with 
molecular probes of rabbit anti-GFP overnight. After wash-
ing in phosphate-buffered solution three times, the sections 
were incubated with goat antirabbit Alexa 488 nm for 1 hour 
and investigated by confocal fluorescence microscope after 
washing by phosphate-buffered solution again. Other sections 
were verified by Prussian blue staining for iron detection.
Percentage of EGFP-positive dendritic 
cells in lymph nodes
For analyzing the percentage of EGPF-positive dendritic cells 
in the lymph nodes, 2 × 106 SPIO-EGFP-labeled dendritic 
cells in 40 µL phosphate-buffered solution were injected 
in the right footpads of the mice preinjected by TNF-α 
(30 ng/leg). The popliteal and inguinal lymph nodes were 
dissected after 48 hours, pooled, disrupted mechanically, 
washed twice with phosphate-buffered solution, fixed in 
2% paraformaldehyde, and the EGFP autofluorescence of 
all lymph nodes was analyzed by flow cytometry.
Results
Characterization of SPIO
Characterization of the synthetic SPIO nanoparticles was 
described according to our previous work.27 Briefly, γ-Fe2O3 
nanoparticles were measured at an average diameter of 
around 8.7 nm under a transmission electron microscope, 
and were found to have formed nearly spherical shape. 
Vibrating sample magnetometer demonstrated that the 
γ-Fe2O3 nanoparticles obtained possessed superparamagnetic 
behavior, with saturation magnetization of 60.4 emu/g. The 
average hydrodynamic size in water was 92 nm and the zeta 
potential of the γ-Fe2O3 nanoparticles had a positive surface 
charge of 20.9 mV .
Efficiency of SPIO-EGFP dendritic cell 
labeling
To evaluate the potential of SPIO particles in tracking 
  dendritic cells by magnetic resonance imaging and   optical 
imaging, the ability of EGFP-labeled dendritic cells to 
phagocytose SPIO particles was first examined. Prussian blue 
staining as well as confocal fluorescence microscopic analysis 
showed that the cells were almost all labeled by SPIO, and 
expressed EGFP fluorescence after being cocultured for 
12 hours with 25 µg/mL SPIO for labeling dendritic cells 
(Figure 1). To evaluate whether the EGFP fluorescence of 
dendritic cells might be influenced by SPIO, a flow cytometry 
assay was undertaken. The results indicated that there was 
no significant difference in fluorescence intensity between 
the labeled and nonlabeled groups (Figure 2).
Magnetic resonance imaging  
of SPIO-labeled dendritic cells in vitro
To define the threshold of magnetic resonance imaging detec-
tion for dendritic cell labeling in vitro, titration experiments 
with different numbers of labeled cells were performed. 
The detectable signal intensities gradually decreased with 
increasing concentration from 1 × 104 cells to 1 × 106 cells 
(Figure 3).
Magnetic resonance imaging in vivo  
and optical imaging ex vivo
Mice were imaged by magnetic resonance imaging, and the 
popliteal lymph nodes were monitored for signs of   dendritic 
cell migration from the injected site using the MSME 
sequence. Within the nodes, a decrease in signal intensity 
(darkening) indicated the presence of SPIO-labeled dendritic 
cells. The homing of dendritic cells into popliteal lymph 
nodes was noninvasively detected by magnetic resonance 
imaging. The darkened image from the popliteal lymph 
node of the right hind leg suggested that SPIO-labeled den-
dritic cells had successfully migrated from the injected site 
(footpad) into the draining lymph nodes (Figure 4A). To 
extend this study, EGFP imaging was performed ex vivo. 
The dissected popliteal lymph nodes were examined by opti-
cal imaging. The results confirmed migration of the SPIO-
EGFP-labeled dendritic cells in bright lymph nodes, which 
was in accordance with the magnetic resonance   imaging 
(Figure 4B, C, and D).
Figure 1 Morphology of dendritic cells labeled with 25 µg/mL superparamagnetic 
iron oxide particles after 12 hours incubation. (A) Labeled dendritic cells (Prussian 
blue  staining,  400×)  and  (B)  green  fluorescence  of  enhanced  green  fluorescent 
protein transgenic dendritic cells (400×).
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SPIO-EGFP-labeled dendritic cells  
in draining lymph nodes
To answer the question of whether dendritic cells migrate 
to lymph nodes after being injected into the footpad of the 
syngeneic mouse, the lymph nodes were dissected, sectioned, 
and subjected to anti-EGFP antibody staining for EGFP 
detection and to Prussian blue staining for iron detection. 
Clear EGFP fluorescence and blue staining localized in 
the cortical area of the popliteal lymph nodes confirmed 
the presence of EGFP and SPIO. By contrast, there was no 
fluorescence or blue staining detected on the control side 
and bilateral inguinal lymph nodes, which indicated that 
no dendritic cells migrated into nondraining and secondary 
draining lymph nodes (Figure 5B).
Migrated dendritic cells in draining  
lymph nodes
After confirmation of migration of SPIO-EGFP-labeled den-
dritic cells into the lymph nodes, the percentage of migrated 
dendritic cells was calculated. Single-cell suspensions of 
draining and non-draining lymph nodes were prepared and 
analyzed by flow cytometry. The mean percentages of EGFP-
positive cells in the right popliteal and inguinal lymph nodes 
were 12.27% and 8.10%, and in the left popliteal and inguinal 
lymph nodes were 5.78% and 5.89%. The   difference between 
the right popliteal lymph nodes and inguinal lymph nodes was 
about 4%, which means about 4% EGFP-positive dendritic 
cells were found in draining popliteal lymph nodes, while the 
result of inguinal lymph nodes was negative (Figure 6).
Discussion
Dendritic cells are the major antigen-presenting cells in the 
initiation and development of the adaptive immune response 
against bacteria, viruses, allergens, and tumor antigens. 
  However, many clinical trials designed to investigate the 
efficacy of dendritic cell vaccines for inducing immunity 
against tumors did not elicit effective antitumor immunity.28,29 
One reason for the lack of therapeutic efficacy was the fact 
that most of the injected dendritic cell vaccines remained 
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Figure 2 Fluorescence intensity of EGFP-transgenic dendritic cells labeled with 25 µg/mL SPIO particles after 12 hours incubation.
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Figure 3 Signal intensity of superparamagnetic iron oxide-labeled dendritic cells 
(25 µg/mL, 12 hours incubation) by magnetic resonance imaging in vitro assay.
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at the injection site and only a few migrated into draining 
lymphatic tissue.10,16 How to track and enhance dendritic cell 
migration in vivo and how to detect these cells by noninvasive 
techniques have become the most urgent questions. In this 
study, we used a combined approach of magnetic resonance 
imaging and optical imaging to explore migration of EGFP-
positive dendritic cells generated from the bone marrow of 
EGFP-transgenic mice, using the technique of synthetic 
SPIO labeling.
SPIO, which is a biodegradable and feasible agent for 
magnetic resonance imaging of living cells both in vitro and 
in vivo,5,22 is an attractive contrast agent for monitoring cell 
migration. Due to the phagocytotic properties and negative 
cytomembrane potential of dendritic cells, SPIO nanoparticles 
could be easily delivered into dendritic cells,30 as indicated 
by Prussian blue staining. The treatments were nontoxic 
and did not interfere with the phenotypes and functions 
of dendritic cells after iron particle internalization.31,32 
EGFP-positive dendritic cells derived from EGFP transgenic 
mice have the advantage of continuous expression of green 
fluorescence compared with other fluorescent dyes. Previous 
results have demonstrated that EGFP is not only a good tool 
for tracking dendritic cell migration, but also a marker of 
viability of dendritic cells, because dying dendritic cells rapidly 
lose their autofluorescence.18 There was strong fluorescence 
of EGFP in all cells on confocal fluorescence microscopy 
(Figure 1). To confirm that the cells migrating into tissues 
were indeed viable SPIO-EGFP-labeled dendritic cells, and 
not nonviable dendritic cells or phagocytes which had taken 
up the dead dendritic cells or released SPIO, the two combined 
techniques of magnetic resonance imaging and optical imaging 
were deployed using the SPIO and EGFP contrast agents.
Before application in vivo, the influence of SPIO labeling 
on the surface molecules, viability, and maturation of the 
dendritic cells were investigated in vitro.31 Briefly, nearly 
100% of the dendritic cells were revealed to contain iron, 
there was little influence on cell apoptosis and expression of 
CD80, CD86, MHC-II, and CCR7 on the surface of mature 
dendritic cells had been little influenced by SPIO labeling.31 
Based on these data, it could be concluded that the SPIO 
nanoparticles possessed good biocompatible characteristics 
and were suitable for use in investigation of the migratory 
behavior and biodistribution of dendritic cells in vivo. 
Another important aspect of dendritic cell migration was 
whether the SPIO could affect the fluorescence intensity 
of EGFP. The results of flow cytometry showed that the 
synthetic SPIO had no influence on the fluorescence signal 
from EGFP dendritic cells (Figure 2).
Figure 5 Morphology of superparamagnetic iron oxide-enhanced green fluorescent 
protein-labeled  dendritic  cells  in  draining  lymph  nodes  after  being  stained  with 
(A) immunohistochemistry and (B) Prussian blue staining (400×).
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Since the immune response based on dendritic cell vaccines 
against tumors is often shown to be weak or localized, how to 
track the migration of dendritic cells in vivo accurately has 
become a major concern. To overcome these deficiencies in 
this study, the two techniques of magnetic resonance imaging 
and optical imaging were combined to explore double-labeled 
dendritic cells from EGFP transgenic mice, in which EGFP 
was continuously expressed during differentiation of bone 
marrow monocytes. Meanwhile, the SPIO had little influence 
on dendritic cells, which served as excellent tools for tracking 
of dendritic cell migration in vivo.
Before the study of dendritic cell migration, the infusion 
method was still under investigation. Footpad injection was 
applied in this study and regarded as an intradermal approach 
because there is little hypodermis located there and it is 
feasible for footpad administration as well. Due to the weak 
migratory ability of dendritic cells in vivo, the footpads were 
pretreated with the inflammatory cytokine, TNF-α (30 ng/leg), 
to increase the migratory ability of dendritic cells by upregu-
lating expression of chemokines in the draining lymph 
nodes.20 As a result, the dendritic cells could easily migrate 
into the draining popliteal lymph nodes (Figure 4).
The disadvantage of common techniques, such as gamma 
scintigraphy, positron emission tomography, and single pho-
ton emission computed tomography, is their lack of spatial 
resolution, a prerequisite for precise anatomical localization 
of migrated dendritic cells in vivo. Due to the high spatial 
resolution and sensitivity of noninvasive imaging, magnetic 
resonance imaging and optical imaging have recently been 
used for tracking magnetic and fluorescent dye double-labeled 
cells in vivo. SPIO-EGFP-labeled dendritic cells were injected 
into the mouse footpads, and strong EGFP and SPIO signals 
could be detected in popliteal lymph nodes areas 48 hours 
later (Figure 4). The percentage of migrated dendritic cells 
into the lymph nodes was about 4% (Figure 6), which is 
similar to other reports,12,18 but less than the 9% reported by 
other researchers.24 The differences may be due to the dif-
ferent calculation method (fluorescence imaging analysis) 
or the method used to count the migration time, such as 
observation after 72 hours following dendritic cell injection. 
Because dendritic cells are specialized antigen-presenting 
cells and larger than T cells, rosettes will be formed when 
T cells encounter dendritic cells. After intradermal injection, 
most dendritic cells remained at the injected site, died, and 
were cleared by macrophages, so only about 4% of dendritic 
cells reached the draining lymph nodes. Limited numbers of 
dendritic cells in the draining lymph nodes are still sufficient 
to induce antigen-specific immunologic responses.10
Noninvasive methods of magnetic resonance imaging and 
optical imaging using SPIO and EGFP labeling enabled us 
to image and analyze dendritic cell migration into draining 
lymph nodes in vivo. The immunohistochemical results dem-
onstrated obvious diffuse distribution of blue iron within the 
lymph node after EGFP-SPIO-labeled dendritic cells were 
injected into the footpad. The confocal assay also confirmed 
that EGFP was present within the lymph node in the experi-
mental side, but EGFP was not detected on the control side 
or secondary draining inguinal lymph node. These results 
are also in accordance with other studies.12,33,34
The data presented here demonstrated migration of 
SPIO-EGFP-labeled dendritic cells by magnetic resonance 
imaging and optical imaging, providing an excellent tool 
to track dendritic cells towards target organs or tissues in 
living organisms. It would be simple to study dendritic cell 
migration. Consequently, initial experiments for tracking of 
fluorescence dye and magnetosome-labeled dendritic cells 
to monitor their dynamic migration in vivo are currently 
being investigated.
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